The fact that essential hypertensive patients with AT1-AAs respond with greater blood pressure reductions to AT1R blockade by candesartan than hypertensive individuals without AT1-AA [29, 30] suggests a causal role for AT1-AAs in at least some cases of hypertension. This evidence concerns the gene AGTR1 and essential hypertension.